Haynes Lab: Difference between revisions
From OpenWetWare
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 15: | Line 15: | ||
<br><br> | <br><br> | ||
CURRENT PROJECTS<br> | CURRENT SYNTHETIC BIOMEDICAL ENGINEERING PROJECTS<br> | ||
'''Synthetic chromatin for cell differentiation''' | '''Synthetic chromatin for cell differentiation''' | ||
* David Barclay (FURI, BS) - pancreas, Jan Simper (FURI, BS) - cardiac | * David Barclay (FURI & SynBERC, BS) - pancreas, Jan Simper (FURI, BS) - cardiac | ||
* Description: Testing the synthetic chromatin protein/ transcription activator described in Haynes & Silver 2011 to | * Description: Testing the "PcTF" synthetic chromatin protein/ transcription activator described in [http://www.ncbi.nlm.nih.gov/pubmed/21669865 Haynes & Silver 2011] to determine its ability to alter the phenotypes of healthy cells, such as pancreas beta cells and iPSC's. | ||
'''Editing synthetic genes using CRISPR''' | '''Editing synthetic genes using CRISPR''' | ||
* René Davis (Biological Design, PhD) | * René Davis (Biological Design, PhD) | ||
* Description: | * Description: Characterizing chromatin/CRISPR interactions. Re-engineering synthetic gene circuits in human cells using CRISPR. | ||
'''Engineering synthetic chromatin transcription factors''' | |||
* Cameron Gardner (FURI, BS) | |||
* Description: Building and testing re-engineered versions of the "PcTF" synthetic chromatin protein/ transcription activator described in [http://www.ncbi.nlm.nih.gov/pubmed/21669865 Haynes & Silver 2011]. | |||
'''Microbial communication with synthetic quorum sensing''' | |||
* René Davis (Biological Design, PhD), Ryan Muller (SOLUR, BS) | |||
* Description: Characterizing cross-talk between decoupled cell-cell communication systems from bacteria. | |||
</div> | </div> | ||
Revision as of 16:49, 13 November 2014
Our group uses synthetic, systems, and quantitative biology to engineer useful gene and protein-based biological devices and to deepen our understanding of molecular cell biology. We operate biological devices primarily in human/ mammalian cells. Accelerating the pace of therapeutic technologies (such as tissue regeneration and customizable protein-based drugs) via modular design is the grand challenge that shapes our research plans.
CURRENT SYNTHETIC BIOMEDICAL ENGINEERING PROJECTS
Synthetic chromatin for cell differentiation
- David Barclay (FURI & SynBERC, BS) - pancreas, Jan Simper (FURI, BS) - cardiac
- Description: Testing the "PcTF" synthetic chromatin protein/ transcription activator described in Haynes & Silver 2011 to determine its ability to alter the phenotypes of healthy cells, such as pancreas beta cells and iPSC's.
Editing synthetic genes using CRISPR
- René Davis (Biological Design, PhD)
- Description: Characterizing chromatin/CRISPR interactions. Re-engineering synthetic gene circuits in human cells using CRISPR.
Engineering synthetic chromatin transcription factors
- Cameron Gardner (FURI, BS)
- Description: Building and testing re-engineered versions of the "PcTF" synthetic chromatin protein/ transcription activator described in Haynes & Silver 2011.
Microbial communication with synthetic quorum sensing
- René Davis (Biological Design, PhD), Ryan Muller (SOLUR, BS)
- Description: Characterizing cross-talk between decoupled cell-cell communication systems from bacteria.
Lab Notebooks - Active
Lab Notebooks - Archived
